Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

EARLY_PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Clear Cell Renal Cell CarcinomaMetastatic Kidney CarcinomaStage IV Renal Cell Cancer AJCC v7

Interventions

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biopsy

Undergo biopsy

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Metastasectomy

Undergo metastasectomy

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo nephrectomy

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER